Amalgamated Bank Grows Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Amalgamated Bank lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,484 shares of the biopharmaceutical company’s stock after acquiring an additional 205 shares during the period. Amalgamated Bank’s holdings in Alnylam Pharmaceuticals were worth $1,996,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Jennison Associates LLC acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $61,160,000. Strategic Financial Concepts LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $41,529,000. Los Angeles Capital Management LLC raised its stake in Alnylam Pharmaceuticals by 11,433.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after acquiring an additional 135,829 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its position in Alnylam Pharmaceuticals by 3.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock valued at $67,464,000 after acquiring an additional 8,462 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in Alnylam Pharmaceuticals by 13.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company’s stock valued at $4,687,000 after acquiring an additional 2,285 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Wolfe Research cut Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. Canaccord Genuity Group boosted their price objective on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th. StockNews.com lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. HC Wainwright upped their price target on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research report on Monday, February 24th. Finally, Needham & Company LLC reissued a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $304.26.

Insider Buying and Selling

In other news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares of the company’s stock, valued at $3,240,344.36. This represents a 10.06 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CMO Pushkal Garg sold 1,752 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $251.00, for a total transaction of $439,752.00. Following the completion of the sale, the chief marketing officer now directly owns 15,705 shares in the company, valued at $3,941,955. This represents a 10.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 72,986 shares of company stock worth $20,397,849. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $246.75 on Monday. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The stock’s 50 day moving average price is $254.32 and its 200 day moving average price is $262.21. The firm has a market cap of $31.94 billion, a P/E ratio of -113.71 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.